Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

Starting soon · Phase 1

Conditions studied: B-cell Non Hodgkin Lymphoma

In brief

This is a Phase 1 interventional, single-arm, open- label, treatment study designed to evaluate the safety of h20.19 CAR T cells in patients with B-cell malignancies that have failed prior therapies.

Key facts

Study ID
NCT07335328
Run by
Medical College of Wisconsin
People needed
24
Starts
2026-09-01
Expected to finish
2031-05-01
Last updated by the study team
2026-06-11

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.